Mitomycin A

Summary

Mitomycin A (CHEMBL298359) is a phase-3 clinical-stage small-molecule antimicrobial agent; indicated across 1 condition including hepatocellular carcinoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Indications: 1 condition
• Chemistry: 349.34 Da · C16H19N3O6

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL298359
Name	Mitomycin A
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	19972
ChEBI	CHEBI:85412
Molecular formula	C16H19N3O6
Molecular weight	349.34
InChIKey	HYFMSAFINFJTFH-NGSRAFSJSA-N

SMILES: CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)OC

IUPAC name: [(4S,6S,7R,8S)-7,11-dimethoxy-12-methyl-10,13-dioxo-2,5-diazatetracyclo[7.4.0.02,7.04,6]trideca-1(9),11-dien-8-yl]methyl carbamate

ChEBI definition: A member of the family of mitomycins that exhibits antibiotic and antitumour properties as well as a high level of toxicity.

Pharmacological roles (ChEBI): toxin, antimicrobial agent, antineoplastic agent, alkylating agent.

Also known as: Mitomycin a, NSC-75986, mitomycin A, Mitomycin A, Nucleoside derivative of mitosene, MITOMYCIN A

Patent coverage: 22 distinct patent families (54 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).